ARCHIT ORGANOSYS LTD.

Archit Organosys Limited has announced September 23, 2026, as the record date for determining shareholders eligible for the final dividend for FY 2025-26. This dividend, recommended by the Board of Directors, is subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for September 30, 2026. The dividend will be paid within 30 days of the AGM to shareholders whose names appear as beneficial owners or in physical share registers by the close of business hours on the record date.

Archit Organosys Ltd announced that its Board of Directors has approved an increase in authorised share capital from ₹25 Crores to ₹60 Crores. The company also approved the issuance of up to 3,72,48,344 equity shares at ₹65 per share via preferential issue, for consideration other than cash. This issuance is for the acquisition of 1,86,24,172 equity shares (92.20% of paid-up capital) of M/s. Archit Life Science Limited, at a valuation of ₹130 per equity share. Both proposals are subject to shareholder approval at the upcoming Annual General Meeting and other regulatory approvals.

Archit Organosys Ltd's Board of Directors has approved an increase in authorized share capital from ₹25 Crores to ₹60 Crores. This move facilitates a preferential issue of up to 3,72,48,344 equity shares at ₹65 per share. The issuance is for consideration other than cash, through a swap of equity shares, to acquire 1,86,24,172 equity shares (92.20% of paid-up equity) of Archit Life Science Limited. The acquisition values Archit Life Science Limited at ₹130 per equity share. Both the capital increase and the share issuance are subject to shareholder approval.

Archit Organosys Ltd has announced that its Board of Directors will convene on September 3, 2026. The primary agenda item is to consider and approve proposals for raising funds through various permissible mechanisms. This may include the issuance of equity shares, share warrants, or other equity-based instruments via preferential issue or private placement, subject to necessary approvals. The company has also closed its trading window for insiders from September 3, 2026, until 48 hours after the information becomes public.

Archit Organosys Ltd has announced a board meeting scheduled for September 3, 2026. The primary agenda is to consider and evaluate proposals for raising funds through various permissible mechanisms, including the issuance of equity shares, warrants, or other equity-based instruments via preferential allotment or private placement. In line with SEBI regulations, the trading window for promoters, directors, senior management, and connected persons has been closed and will reopen 48 hours after the information becomes public.

Archit Organosys Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors, upon recommendation from the Audit Committee, reviewed and approved the results. The company reported a total income of ₹3768.67 Lacs and a net profit of ₹144.70 Lacs for the quarter. The limited review report from the statutory auditors was also attached. The board meeting commenced at 12:45 p.m. and concluded at 1:15 p.m. on August 12, 2026.

Archit Organosys Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors, following the recommendation of the Audit Committee, reviewed and approved these results during their meeting held on August 12, 2026. The limited review report from the statutory auditors was also approved and attached to the filing. The board meeting commenced at 12:45 p.m. and concluded at 01:15 p.m.

Archit Organosys Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda for this meeting is to consider and approve the company's Unaudited Financial Results for the quarter ending June 30, 2026. In line with SEBI regulations, the trading window for designated personnel has been closed from July 1, 2026, and will reopen 48 hours after the results are made public.

Archit Organosys Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct. The window will be shut from Wednesday, July 1, 2026, and will reopen 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The specific date for the Board of Directors' meeting to approve these results will be intimated separately.

Archit Organosys Ltd approved the audited standalone financial results for the quarter and financial year ended March 31, 2026, in a board meeting held on May 16, 2026. The board also recommended a final dividend of ₹1 per equity share (10%) of ₹10 each for the financial year ended March 31, 2026. The auditor's report, issued by M/s G.K. Choksi & Co, Chartered Accountants, has an unmodified opinion on the standalone audited financial results.